Holloway, C. Lamp, H. Anderson, M. J. Yoon; Cubist Pharmaceuticals, Lexington, MA. L. Davis

161 TUESDAY SCIENTIFIC SESSIONS Final Program K-1629 A Randomized Controlled Trial to Evaluate a Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients STOP-NT J. J. Carreno 1,2 , S. L. Davis 1,2 , R. M. Chambers 2 , J. A. Vazquez 2 ; 1 Wayne State Univ. Coll. of Pharmacy, Detroit, MI, 2 Henry Ford Hosp., Detroit, MI. K-1630 Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia and Vancomycin Minimum Inhibitory Concentration in Hemodialysis Patients

G. A. Patel, R. Sharma; State Univ. of New York Downstate Med. Ctr., Brooklyn, NY.

K-1631 Efficacy and Safety of Daptomycin DAP in the Treatment of Gram-Positive Infections in Patients with Renal Impairment

R. Kullar

1 , I. McClellan 2 , M. Geriak 3 , G. Sakoulas 3 ; 1 Oregon State Univ. Oregon Hlth. Sci. Univ, Portland, OR, 2 Oregon State Univ., Portland, OR, 3 Sharp Mem. Hosp., San Diego, CA. K-1632 Enterococcal Bloodstream Infection During Neutropenic Fever: Impact of Vancomycin Resistance on Mortality

S. Cho

1 , D. Lee 1 , J. Choi 1 , J. Kwon 2 , S. Kim 3 , S. Choi 1 , S. Park 1 , J. Choi 1 , J. Yoo 1 ; 1 Coll. of Med., The Catholic Univ. of Korea, Seoul, Korea, Republic of, 2 Ilsan Hosp., Goyang-si Gyeonggi-do, Korea, Seoul, Korea, Republic of, 3 Coll. of Med., The Korea Univ. of Korea, Seoul, Korea, Republic of. K-1633 Cost-Effectiveness Analysis of Linezolid LIN, Daptomycin DAP and Vancomycin VAN in Methicillin-Resistant Staphylo- coccus aureus MRSA Complicated Skin and Soft Tissue Infec- tions cSSTI from a Spanish Perspective S. Grau 1 , M. M. Alonso-Socas 2 , J. Rodríguez-Baño 3 , A. Soriano 4 , M. Trikic 5 , M. De Salas-Cansado 5 ; 1 Hosp. del Mar, Barcelona, Spain, 2 Univ. Hosp. of Tenerife, Tenerife, Spain, 3 Hosp. Virgen de la Macarena, Sevilla, Spain, 4 Hosp. Clìnic, Barcelona, Spain, 5 Pfizer, Madrid, Spain. K-1634 Treatment and Outcomes of Patients with Daptomycin Non-Susceptible

S. aureus Associated Infection

N. Fattouh, B. Ostrowsky, Y. Guo; Montefiore Med. Ctr., Bronx, NY. K-1635

Daptomycin DAP Outcomes in Patients Pts with Severe Sepsis Due to Staphylococcal Bacteremia SB with Vancomycin VAN MICs of 2 mgL K. Holloway, K. C. Lamp, H. Anderson, M. J. Yoon; Cubist Pharmaceuticals, Lexington, MA. K-1636 Daptomycin Resistance Following Vancomycin Failure in Invasive Methicillin-Resistant Staphylococcus aureus Bacteremia K. A. Bauer, J. Wong, J. Gaborcik Candidate, D. A. Goff; The Ohio State Univ. Med. Ctr., Columbus, OH. ------------------------------------------------------------------------ 186 L1 Poster Session Endocarditis and Other Invasive Infections Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: L1-1637 Endocarditis from Enterococcus faecalis A. R. Cremona, Losinno Juan, Ramirez Santiago, Blanco Miriam, Cazzola Laura, Firpo Soledad, Yebara Analia; Hosp. Italiano, La Plata, Argentina. L1-1638 Comparison of High Dose Daptomycin DAP and Dose Optimized Vancomycin VAN for MRSA Bacteremia and Infective Endocarditis IE

S. L. Davis

1,2 , M. J. Rybak 1,3,4 , J. A. Vazquez 2,4 , E. Hershberger 5 , P. Bernardo 5 , D. P. Levine 4,3 ; 1 Wayne State Univ. Coll. of Pharmacy, Detroit, MI, 2 Henry Ford Hosp., Detroit, MI, 3 Detroit Med. Ctr., Detroit, MI, 4 Wayne State Univ. Sch. of Med., Detroit, MI, 5 Cubist Pharmaceuticals, Lexington, MA. L1-1639 578 Endocarditis in French Region: Epidemiology, Mortality and Cost S. Sunder 1 , S. Baron 1 , F. Bastides 1 , T. Prazuck 2 , Y. Guimard 3 , A. Valery 2 , M. Massot 3 , L. Bernard 1 ; 1 CHRU de Tours, Tours, France, 2 CHR d’Orléans, Orléans, France, 3 CH de Bourges, Bourges, France. L1-1640 Relation Between Specific Bacteria, Echocardiographic Findings, and Surgical Findings in Patients Undergoing Cardiac Surgery Due to Infectious Endocarditis

Y. Maor, A. Akuka, D. Ben David, N. Keller G. Rahav; Sheba Med. Ctr., Tel Hashomer, Israel.